Research & Innovation | Overview
In the Brain Tumor Center, the care we provide is driven by the latest research. Our team members are leaders in pediatric brain tumor research — and our findings are helping improve our understanding of brain tumors and transform their treatment.
Explore some of our latest research
Areas of active research
- Atypical teratoid rhabdoid tumors
- CAR T-cell therapy
- Diffuse intrinsic pontine gliomas
- Embryonal tumors with multilayered rosettes
- Ependymomas
- Hemispheric high-grade gliomas and gliomatosis cerebri
- Pediatric low-grade gliomas
Clinical trials
The Brain Tumor Center is a member of several major clinical trial consortia. These include the Children’s Oncology Group (COG), the Pediatric Neuro-Oncology Consortium (PNOC), the CONNECT Consortium, and the Pediatric Brain Tumor Consortium (PBTC). This means that we can provide our patients with access to a wide range of clinical trials.
Selected publications
- Cellular hierarchies of embryonal tumors with multilayered rosettes are shaped by oncogenic microRNAs and receptor-ligand interactions: https://pubmed.ncbi.nlm.nih.gov/40419763/
- Dissecting the immune landscape in pediatric high-grade glioma reveals cell state changes under therapeutic pressure: https://pubmed.ncbi.nlm.nih.gov/40315846/
- Neuroimmune-competent human brain organoid model of diffuse midline glioma: https://pubmed.ncbi.nlm.nih.gov/39561098/
- Paediatric strategy forum for medicinal product development in diffuse midline gliomas in children and adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration: https://pubmed.ncbi.nlm.nih.gov/39854822/
- SMARCB1 missense mutants disrupt SWI/SNF complex stability and remodeling activity: https://pubmed.ncbi.nlm.nih.gov/40196006/
- Treatment Approach for Metastatic Intracranial Germinoma: A Multi-Institutional Experience: https://pubmed.ncbi.nlm.nih.gov/40038880/
- A diverse landscape of FGFR alterations andco-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas: https://pubmed.ncbi.nlm.nih.gov/40744913/
- Effective targeting of PDGFRA-altered high-grade glioma with avapritinib: https://pubmed.ncbi.nlm.nih.gov/40086436/
- H3K27-altered diffuse midline gliomas with MAPK pathway alterations: Prognostic and therapeutic implications: https://pubmed.ncbi.nlm.nih.gov/38037182/